Oncology & Cancer

JAK inhibitors associated with aggressive lymphoma

Austrian researchers have discovered that a small number of patients taking targeted drugs known as Janus kinase (JAK) inhibitors to treat myelofibrosis may develop aggressive lymphomas.

Oncology & Cancer

New epigenetic drug against Mantle Cell Lymphoma

A new study by doctor Manel Esteller, Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL), ICREA Researcher and Professor of Genetics at the University of ...

Oncology & Cancer

FDA approves CAR T therapy for large B-cell lymphoma

The U.S. Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania's Abramson Cancer Center, this time for the treatment of adult patients with ...

Oncology & Cancer

Immune-engineered device targets chemo-resistant lymphoma

Non-Hodgkin lymphoma, a cancer that is diagnosed in the U.S. more than 70,000 times annually, arises from overly proliferating immune cells within the body's lymph nodes, which are connected to a network of lymph vessels ...

Oncology & Cancer

Attacking lymphoma at the source

Non-Hodgkin lymphomas are cancers that affect white blood cells of the immune system called B-lymphocytes, or B cells. Like cells in all cancers, the B cells begin to grow out of control, creating tumors in the lymph nodes, ...

Oncology & Cancer

Epigenetics therapy shows promise in patients with lymphoma

New compounds targeting epigenetics have shown remarkable early activity in patients with lymphoma, according to data presented at the TAT (Targeted Anticancer Therapies) International Congress 2018 in Paris, France. ESMO's ...

Oncology & Cancer

Genetic test identifies 'high risk' lymphatic cancer patients

Around 1,500 people in Denmark are diagnosed with lymphatic cancer each year. A small sub-group (70 to 80 people) develop a rare and aggressive type of lymphatic cancer, known as mantle cell lymphoma (MCL).

page 23 from 40